Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

NCT03704688 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
KRAS Gene Mutation

Interventions

DRUG: Trametinib 0.5 mg
DRUG: Trametinib 1 MG
DRUG: Trametinib 1.5 MG
DRUG: Trametinib 2 mg
DRUG: Ponatinib 15 MG
DRUG: Ponatinib 30 MG

Sponsor

Memorial Sloan Kettering Cancer Center